TY - JOUR
T1 - Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas
T2 - results from the ReSPOND consortium
AU - ReSPOND Consortium
AU - Lee, Matthew D
AU - Patel, Sohil H
AU - Mohan, Suyash
AU - Akbari, Hamed
AU - Bakas, Spyridon
AU - Nasrallah, MacLean P
AU - Calabrese, Evan
AU - Rudie, Jeffrey
AU - Villanueva-Meyer, Javier
AU - LaMontagne, Pamela
AU - Marcus, Daniel S
AU - Colen, Rivka R
AU - Balana, Carmen
AU - Choi, Yoon Seong
AU - Badve, Chaitra
AU - Barnholtz-Sloan, Jill S
AU - Sloan, Andrew E
AU - Booth, Thomas C
AU - Palmer, Joshua D
AU - Dicker, Adam P
AU - Flanders, Adam E
AU - Shi, Wenyin
AU - Griffith, Brent
AU - Poisson, Laila M
AU - Chakravarti, Arnab
AU - Mahajan, Abhishek
AU - Chang, Susan
AU - Orringer, Daniel
AU - Davatzikos, Christos
AU - Jain, Rajan
N1 - © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Funding Information:
This project was partially supported by National Institutes of Health/National Cancer Institute (R01CA269948).
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Funding Information:
This study was previously presented as a poster at the Society for Neuro-Oncology annual meeting in Tampa, Florida on November 18, 2022, and as an oral presentation at the Radiological Society of North America annual meeting in Chicago, Illinois on November 27, 2022. The ReSPOND Consortium also includes: Stephen J. Bagley1,2, Michel Bilello3,4, Steven Brem5,1, Ujjwal Baid3,6, Arati S. Desai1,2, Robert A. Lustig7, Elizabeth Mamourian3,6, Anahita Fathi Kazerooni8,9,3, Jose A. Garcia3,6, Donald M. O’Rourke5,1, Zev A. Binder1, Mikhail Milchenko10, Arash Nazeri10, Aris Sotiras10, Murat Ak11, Jaume Capellades12, Josep Puig13, Sung Soo Ahn14, Jong Hee Chang15,16, Seung-Koo Lee14, Yae Won Park14, Vachan Vadmal17, Kristin A. Waite18, Sree Gongala19, Alysha Chelliah20, Golestan Karami20, Gregory S. Alexander21, Ayesha S. Ali22, Spencer Liem22, Joseph Lombardo22,23, Gaurav Shukla22,24,3, Muhammad Sharif22, Lisa R. Rogers25, William Taylor26, Santiago Cepeda27, Aikaterini Kotrotsou28, Hassan Fathallah-Shaykh29, Orazio Santo Santonocito30, Anna Luisa Di Stefano30, Aaron M. Rulseh31, Yuji Matsumoto32, Kimberley Alexander33,34,35, Laveniya Satgunaseelan36, Benedikt Wiestler37, Rao P. Gullapalli38, Elias R. Melhem38, Graeme F. Woodworth38,39, Peter I. Kamel40, Victor M. Perez-Garcia41, Alekos Vamvakas42, Yiannis Tsougos42, Pablo Valdes43, Pallavi Tiwari44, Mariam Aboian45,46,471Glioblastoma Multiforme Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA2Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA3Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA4Department of Radiology, Division of Neuroradiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA5Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA6Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA7Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA8Center for Data Driven Discovery in Biomedicine, Children’s Hospital of Philadelphia, Philadelphia, PA, USA9Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA10Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA11Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA12Department of Medical Imaging, Consorci MAR Parc de Salut, Barcelona, Spain13Research Unit (IDIR) Image Diagnosis Institute, Badalona, Spain14Department of Radiology, Section of Neuroradiology, Yonsei University Health System, Seoul, South Korea15Department of Neurosurgery, Yonsei University College of Medicine, Seoul, South Korea16Brain Tumor Center, Severance Hospital, Yonsei University Health System, Seoul, South Korea17Department of Population and Quantitative Health Sciences, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA18Trans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA19Department of Radiology, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA20School of Biomedical Engineering and Imaging Sciences, King’s College London, London, UK21Department of Radiation Oncology, University of Maryland, Baltimore, MD, USA22Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA23Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA24Department of Radiation Oncology, Christiana Care Health System, Philadelphia, PA, USA25Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Cancer Institute, Henry Ford Health, Detroit, MI, USA26Department of Radiation Oncology and Neurosurgery, The James Cancer Hospital at the Ohio State University Wexner Medical Center, Columbus, OH, USA27Department of Neurosurgery, University Hospital Río Hortega, Valladolid, Spain28MD Anderson Cancer Center, University of Texas, Houston, TX, USA29Department of Neurology, The University of Alabama at Birmingham, Birmingham, AL, USA30Division of Neurosurgery, Spedali Riuniti di Livorno-Azienda USL Toscana Nord-Ovest, Livorno, Italy31Department of Radiology, Na Homolce Hospital, Prague, Czech Republic32Department of Neurological Surgery, Okayama University, Okayama, Japan33Chris O’Brien Lifehouse, Camperdown, Australia34University of Sydney, Camperdown, Australia35Sydney Local Health District, Camperdown, Australia36Department of Pathology Services, Royal Prince Alfred Hospital, Camperdown, Australia37Department of Neuroradiology, Technical University of Munich, Munchen, Germany38Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA39Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD, USA40Department of Diagnostic Radiology and Nuclear Medicine, Intelligent Imaging (UM2ii) Center, University of Maryland School of Medicine, Baltimore, MD, USA41Mathematical Oncology Laboratory (MOLAB), University of Castilla-La Mancha, Ciudad Real, Spain42Medical School of the University of Thessaly, Larissa, Greece43University of Texas Medical Branch, Galveston, TX, USA44Department of Radiology and Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA45Clinical Advanced Image Processing Lab (CAIP), Yale School of Medicine, New Haven, CT, USA46Brain Tumor Research Group (ImagineQuant), Yale School of Medicine, New Haven, CT, USA47Section of Neuroradiology and Nuclear Medicine, Yale School of Medicine, New Haven, CT, USA ORCIDs: Stephen J. Bagley, https://orcid.org/0000-0002-7117-0539 ; Michel Bilello, https://orcid.org/0000-0001-6313-5437 ; Steven Brem, https://orcid.org/0000-0002-5803-8920 ; Ujjwal Baid, https://orcid.org/0000-0001-5246-2088 ; Arati S. Desai, https://orcid.org/0000-0002-4849-4703 ; Robert A. Lustig, https://orcid.org/0000-0003-0633-3802 ; Elizabeth Mamourian, http://orcid.org/0000-0001-8581-4887 ; Anahita Fathi Kazerooni, https://orcid.org/0000-0001-7131-2261 ; Donald M. O’Rourke, https://orcid.org/0000-0002-8479-7314 ; Zev A. Binder, https://orcid.org/0000-0003-1158-231X ; Mikhail Milchenko, https://orcid.org/0000-0002-4022-1081 ; Arash Nazeri, https://orcid.org/0000-0001-6983-0641 ; Aris Sotiras, https://orcid.org/0000-0003-0795-8820 ; Murat Ak, https://orcid.org/0000-0001-7384-478X ; Jaume Capellades, https://orcid.org/0000-0002-1417-4496 ; Josep Puig, https://orcid.org/0000-0003-2791-6599 ; Sung Soo Ahn, https://orcid.org/0000-0002-0503-5558 ; Jong Hee Chang, https://orcid.org/0000-0003-1509-9800 ; Seung-Koo Lee, https://orcid.org/0000-0001-5646-4072 ; Yae Won Park, https://orcid.org/0000-0001-8907-5401 ; Kristin A. Waite, https://orcid.org/0000-0002-3186-8510 ; Alysha Chelliah, https://orcid.org/0000-0003-0867-1565 ; Golestan Karami, https://orcid.org/0000-0002-8107-3812 ; Gregory S. Alexander, http://orcid.org/0000-0003-1907-7828 ; Santiago Cepeda, https://orcid.org/0000-0003-1667-8548 ; Aikaterini Kotrotsou, https://orcid.org/0000-0002-0433-7159 ; Hassan Fathallah-Shaykh, https://orcid.org/0000-0002-2690-7685 ; Orazio Santo Santonocito, https://orcid.org/0000-0002-1071-7166 ; Anna Luisa Di Stefano, https://orcid.org/0000-0003-1746-0647 ; Aaron M. Rulseh, https://orcid.org/0000-0002-8332-4419 ; Yuji Matsumoto, https://orcid.org/0000-0001-8798-381X ; Kimberley Alexander, https://orcid.org/0000-0002-7239-039X ; Laveniya Satgunaseelan, https://orcid.org/0000-0002-7435-0834 ; Benedikt Wiestler, https://orcid.org/0000-0002-2963-7772 ; Rao P. Gullapalli, https://orcid.org/0000-0003-0551-0379 ; Victor M. Perez-Garcia, https://orcid.org/0000-0002-6575-495X ; Yiannis Tsougos, https://orcid.org/0000-0002-5204-5273 ; Pallavi Tiwari, https://orcid.org/0000-0001-9477-4856 ; Mariam Aboian, https://orcid.org/0000-0002-4877-8271
Funding Information:
This project was partially supported by National Institutes of Health/National Cancer Institute (R01CA269948).
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2023/9
Y1 - 2023/9
N2 - Purpose: While the T2-FLAIR mismatch sign is highly specific for isocitrate dehydrogenase (IDH)-mutant, 1p/19q-noncodeleted astrocytomas among lower-grade gliomas, its utility in WHO grade 4 gliomas is not well-studied. We derived the partial T2-FLAIR mismatch sign as an imaging biomarker for IDH mutation in WHO grade 4 gliomas. Methods: Preoperative MRI scans of adult WHO grade 4 glioma patients (n = 2165) from the multi-institutional ReSPOND (Radiomics Signatures for PrecisiON Diagnostics) consortium were analyzed. Diagnostic performance of the partial T2-FLAIR mismatch sign was evaluated. Subset analyses were performed to assess associations of imaging markers with overall survival (OS). Results: One hundred twenty-one (5.6%) of 2165 grade 4 gliomas were IDH-mutant. Partial T2-FLAIR mismatch was present in 40 (1.8%) cases, 32 of which were IDH-mutant, yielding 26.4% sensitivity, 99.6% specificity, 80.0% positive predictive value, and 95.8% negative predictive value. Multivariate logistic regression demonstrated IDH mutation was significantly associated with partial T2-FLAIR mismatch (odds ratio [OR] 5.715, 95% CI [1.896, 17.221], p = 0.002), younger age (OR 0.911 [0.895, 0.927], p < 0.001), tumor centered in frontal lobe (OR 3.842, [2.361, 6.251], p < 0.001), absence of multicentricity (OR 0.173, [0.049, 0.612], p = 0.007), and presence of cystic (OR 6.596, [3.023, 14.391], p < 0.001) or non-enhancing solid components (OR 6.069, [3.371, 10.928], p < 0.001). Multivariate Cox analysis demonstrated cystic components (p = 0.024) and non-enhancing solid components (p = 0.003) were associated with longer OS, while older age (p < 0.001), frontal lobe center (p = 0.008), multifocality (p < 0.001), and multicentricity (p < 0.001) were associated with shorter OS. Conclusion: Partial T2-FLAIR mismatch sign is highly specific for IDH mutation in WHO grade 4 gliomas.
AB - Purpose: While the T2-FLAIR mismatch sign is highly specific for isocitrate dehydrogenase (IDH)-mutant, 1p/19q-noncodeleted astrocytomas among lower-grade gliomas, its utility in WHO grade 4 gliomas is not well-studied. We derived the partial T2-FLAIR mismatch sign as an imaging biomarker for IDH mutation in WHO grade 4 gliomas. Methods: Preoperative MRI scans of adult WHO grade 4 glioma patients (n = 2165) from the multi-institutional ReSPOND (Radiomics Signatures for PrecisiON Diagnostics) consortium were analyzed. Diagnostic performance of the partial T2-FLAIR mismatch sign was evaluated. Subset analyses were performed to assess associations of imaging markers with overall survival (OS). Results: One hundred twenty-one (5.6%) of 2165 grade 4 gliomas were IDH-mutant. Partial T2-FLAIR mismatch was present in 40 (1.8%) cases, 32 of which were IDH-mutant, yielding 26.4% sensitivity, 99.6% specificity, 80.0% positive predictive value, and 95.8% negative predictive value. Multivariate logistic regression demonstrated IDH mutation was significantly associated with partial T2-FLAIR mismatch (odds ratio [OR] 5.715, 95% CI [1.896, 17.221], p = 0.002), younger age (OR 0.911 [0.895, 0.927], p < 0.001), tumor centered in frontal lobe (OR 3.842, [2.361, 6.251], p < 0.001), absence of multicentricity (OR 0.173, [0.049, 0.612], p = 0.007), and presence of cystic (OR 6.596, [3.023, 14.391], p < 0.001) or non-enhancing solid components (OR 6.069, [3.371, 10.928], p < 0.001). Multivariate Cox analysis demonstrated cystic components (p = 0.024) and non-enhancing solid components (p = 0.003) were associated with longer OS, while older age (p < 0.001), frontal lobe center (p = 0.008), multifocality (p < 0.001), and multicentricity (p < 0.001) were associated with shorter OS. Conclusion: Partial T2-FLAIR mismatch sign is highly specific for IDH mutation in WHO grade 4 gliomas.
UR - http://www.scopus.com/inward/record.url?scp=85165155830&partnerID=8YFLogxK
U2 - 10.1007/s00234-023-03196-9
DO - 10.1007/s00234-023-03196-9
M3 - Article
C2 - 37468750
SN - 1432-1920
VL - 65
SP - 1343
EP - 1352
JO - Neuroradiology
JF - Neuroradiology
IS - 9
ER -